BeiGene

BeiGene is a global biotechnology company committed to bringing patients worldwide better treatment options through clinical trials. The company has a workforce of over 10,000 employees and operates in 40 countries on five continents. Known for its innovative oncology medicines, BeiGene has one of the world’s largest oncology research teams and a broad pipeline with the potential to address 80% of the world’s cancers by type. Its notable products include BRUKINSA, a small molecule inhibitor of Bruton’s tyrosine kinase (BTK), approved for various B-cell malignancies in 70 markets, and TEVIMBRA, a humanized monoclonal antibody targeting the PD-1 receptor, approved for various solid tumors globally. BeiGene collaborates with major biopharmaceutical companies like Amgen, Bristol Myers Squibb for Celgene, and Novartis. The company is traded on the NASDAQ, the Hong Kong Stock Exchange, and the Shanghai Stock Exchange, and is headquartered in Basel, Beijing, and Cambridge, Mass. BeiGene manufactures and markets Brukinsa (zanubrutinib), Tislelizumab (BGB-A317), and Pamiparib (BGB-290), with a market capitalization of approximately $23 billion. Its global presence spans Asia, Australia, Europe, Latin America, and North America, and it recruits for clinical trials across a wide range of therapeutic indications, including lymphoma, liver cancers, lung cancers, gastric cancers, and breast cancers. BeiGene focuses on diversity in clinical trials to improve research, treatments, and health outcomes for all people. The company offers a Patient Support Program and Expanded Access Programs, and is committed to responsible business practices and sustainability. BeiGene also has a dedicated BeiGene Foundation and provides Independent Medical Education Grants. In 2024, Fast Company named BeiGene one of the World’s Most Innovative Companies.